Experimental CAR T-Cell therapy aims to tame tough lupus cases

This early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and destroy faulty B-cells, which drive lupus activity. About 162 adults aged 18-75 with highly active lupus will receive the therapy in a hospital setting, and researchers will monitor safety, side effects, and how well it controls the disease. This is not a cure, as ongoing management may still be needed.